1Campbell RK. Glimepiride: Role of a new suffonylurea in the treatnent of type 2 diabetes mellitus. Ann Pharmacother 1998;32:1044.
2Muller G, Hartz D, Punter J, Okonomopulos R, Kramer W. Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1994; 1191: 267.
3Schade DS, Jovanovic - Peterson L, Schneider J. A phacebo- controlled dose - titration study of glimepiride in patients with non - insulin - dependent diabetes mellitus (NIDDM).Hoechst Marion Roussel Inc., 1997.
4Sonenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, et al. Shortterm comparison of once - versus twice- daily administration of glimepiride in patients with non - insulin- dependent diabetes mellitus. Ann Pharmacother 1997; 31:671.
5Goldberg RB, Holvey SM, Schneider J, The Glimepiride Protocol# 201 Study Group. A dose response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996; 19: 847.
6Dills DG, Schneider J, The Glimepiride/Glyburide Study Group. Clinical evaluation of glimepiride versus glyburied in NIDDM in a double - bline comparative study. Horm Metah Res 1996;28:426.
7Clark CM, Goldberg RB. Glimepiride dosing and efficacy;results of pacebo - controlled, dose - regimen, and active - controlled triabls. In: White - house F, Gavin J, eds. Postgraduate medicine special reprot: therapeutic strategies for managing NIDDM. Minneapolis: McGraw - Hill Healthcare Information Group,June 1997;45.
8Schneider J, Chaikin P, limepiride safety. Results of placebo- con - trolled, dose - regimen, and active - controlled trials.In:Whitehouse F, Gavin J, eds. Postgraduate medicine special report: therapeutic strategies for managing NIDDm. Minneapolis:McGraw - Hill Healthcare Information Group, June 1997 ;33.
2[1]Cambell RK.Glimepiride:Role of new sulfonylurea in the treatment of type 2 diabetes mellitus.Ann Pharmacother,1998,32:1 044.
3[2]Haffner SM,Gonzalez C,Mietnen H,et al.A prospective analysis of the HOMA model.The Mexico City Diabetes Study.Diabtes Care,1997,20:1 138-1 141.
4[3]Korytkowski M,Thoms A,Reid L,et al.Glimepiride improves both first and second phase of insulin secretion in type 2 diabetes.Diabetes Care,2002,25(9):1 607-1 611.
5[4]Rosak C.The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.J Diabetes Complication,2002,16(1):123-132.
6[7]Muller G,Hartz D,Punter J,et al.Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor.I.Binding Characteristics.Biochim Biophys Acta,1994,1191:267.
7Sonenberg GE, Garg DC, Weidler DJ,et al. Shotterm comparison of onceversus twice daily administration of glimepiride in patients with non - insulin dependent diabetes mellitus. Ann Pharmacother, 1997,31:671.
8Korytkowski M,Thoms A,Reid L,et al.Glimepiride improves both first and second phase of insulin secretion in type 2 diabetes[J].Diabetes Care,2002,25 (9):1 607-1 611.
